Oramed Pharmaceuticals Inc. Selected to Present at the 73rd Scientific Sessions of the American Diabetes Association in Chicago, IL, June 21-25, 2013
Published: Mar 22, 2013
About the American Diabetes Association (ADA) Scientific Sessions
The ADA's Scientific Sessions brings together scientists and health care professionals from around the world who are involved in diabetes research and care. The five-day meeting features the most timely and significant advances in the prevention, diagnosis, and treatment of diabetes. The program is organized into eight distinctive theme areas and includes presentation by world-renowned diabetes experts.
For more information on the ADA, please refer to their website: http://www.diabetes.org
More information on the Scientific Sessions can be found here.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently approaching Phase 2 clinical trials under U.S. IND, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), currently approaching Phase 2a trials. The company's corporate and R&D headquarters are based in Jerusalem.